Lung Cancer

Study Title

A Randomized Phase III Comparison of Standard Dose (60 Gy) Versus High Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab in Patients with Stage IIIA/IIIB Non Small Cell.

Prinicipal Investigators

• Mack Roach, MD, UCSF Department of Radiation Oncology
• Sue Yom, MD, UCSF Department of Radiation Oncology

Study Number

RTOG 0617/NCCTG N0628/CALGB 30609

Status of Trial

Open

Why is this study being done?

One purpose of this study is to compare the effects, good and/or bad, of high-dose radiation therapy with standard dose radiation therapy on you and your Stage III non-small cell lung cancer to find out which is better.  In this study, you will get either the high-dose or the standard dose radiation therapy.  You will not get both.  Everyone will get the chemotherapy with the same drug combination and schedule, consisting of paclitaxel and carboplatin.

In addition, this study will compare the effects, good and/or bad, of adding Cetuximab to radiation and chemotherapy.  In this study, you will get radiation and chemotherapy or radiation, chemotherapy, and Cetuximab.

Cetuximab is a drug that may delay or prevent tumor growth by blocking certain cellular chemical pathways that lead to tumor development. It has been approved by the FDA as a treatment for patients with colorectal and head and neck cancer. Cetuximab has not yet been approved as a treatment for patients with lung cancer and is considered experimental in this study.

Contact

Marilyn Robinson, CCRP
Clinical Research Coordinator-Supervisor
Voice: 415/353.4294
Email: robinsonmg@radonc.ucsf.edu

PDF

Download the PDF of full trial description and consent form